<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">mSystems</journal-id>
    <journal-id journal-id-type="iso-abbrev">mSystems</journal-id>
    <journal-id journal-id-type="hwp">msys</journal-id>
    <journal-id journal-id-type="pmc">msys</journal-id>
    <journal-id journal-id-type="publisher-id">mSystems</journal-id>
    <journal-title-group>
      <journal-title>mSystems</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2379-5077</issn>
    <publisher>
      <publisher-name>American Society for Microbiology</publisher-name>
      <publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">6787565</article-id>
    <article-id pub-id-type="pmid">31594829</article-id>
    <article-id pub-id-type="publisher-id">mSystems00413-19</article-id>
    <article-id pub-id-type="doi">10.1128/mSystems.00413-19</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Opinion/Hypothesis</subject>
      </subj-group>
      <subj-group subj-group-type="overline">
        <subject>Therapeutics and Prevention</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title><italic>MetaMed</italic>: Linking Microbiota Functions with Medicine Therapeutics</article-title>
      <alt-title alt-title-type="running-head">Opinion/Hypothesis</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Zhao</surname>
          <given-names>Han</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>a</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Fu</surname>
          <given-names>Shaliu</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>a</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="no">
        <name>
          <surname>Yu</surname>
          <given-names>Yifei</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>a</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="no">
        <name>
          <surname>Zhang</surname>
          <given-names>Zhanbing</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>a</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="no">
        <name>
          <surname>Li</surname>
          <given-names>Ping</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>a</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="no">
        <name>
          <surname>Ma</surname>
          <given-names>Qin</given-names>
        </name>
        <xref ref-type="aff" rid="aff5">
          <sup>e</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="no">
        <name>
          <surname>Jia</surname>
          <given-names>Wei</given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
          <sup>d</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="no">
        <name>
          <surname>Ning</surname>
          <given-names>Kang</given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
          <sup>c</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" equal-contrib="no">
        <name>
          <surname>Qu</surname>
          <given-names>Shen</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>a</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" equal-contrib="no">
        <name>
          <surname>Liu</surname>
          <given-names>Qi</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>a</sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
          <sup>b</sup>
        </xref>
      </contrib>
      <aff id="aff1">
        <label>a</label>
        <addr-line>Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, and Bioinformatics Department, School of Life Sciences and Technology, Tongji University, Shanghai, China</addr-line>
      </aff>
      <aff id="aff2">
        <label>b</label>
        <addr-line>Department of Ophthalmology, Ninghai First Hospital, Ninghai, Zhejiang, China</addr-line>
      </aff>
      <aff id="aff3">
        <label>c</label>
        <addr-line>School of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China</addr-line>
      </aff>
      <aff id="aff4">
        <label>d</label>
        <addr-line>R&amp;D Information, Innovation Center China, AstraZeneca, Shanghai, China</addr-line>
      </aff>
      <aff id="aff5">
        <label>e</label>
        <addr-line>Department of Mathematics and Statistics, South Dakota State University, Brookings, South Dakota, USA</addr-line>
      </aff>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Jansson</surname>
          <given-names>Janet K.</given-names>
        </name>
        <role>Editor</role>
        <aff>Pacific Northwest National Laboratory</aff>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="cor1">Address correspondence to Shen Qu, <email>qushencn@hotmail.com</email>, or Qi Liu, <email>qiliu@tongji.edu.cn</email>.</corresp>
      <fn fn-type="equal">
        <p>H.Z. and S.F. contributed equally.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>Citation</bold> Zhao H, Fu S, Yu Y, Zhang Z, Li P, Ma Q, Jia W, Ning K, Qu S, Liu Q. 2019. <italic>MetaMed</italic>: linking microbiota functions with medicine therapeutics. mSystems 4:e00413-19. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/mSystems.00413-19">https://doi.org/10.1128/mSystems.00413-19</ext-link>.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>8</day>
      <month>10</month>
      <year>2019</year>
    </pub-date>
    <pub-date pub-type="collection">
      <season>Sep-Oct</season>
      <year>2019</year>
    </pub-date>
    <volume>4</volume>
    <issue>5</issue>
    <elocation-id>e00413-19</elocation-id>
    <permissions>
      <copyright-statement>Copyright © 2019 Zhao et al.</copyright-statement>
      <copyright-year>2019</copyright-year>
      <copyright-holder>Zhao et al.</copyright-holder>
      <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
        <license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="mSystems.00413-19.pdf"/>
    <abstract abstract-type="precis">
      <p>Understanding how the human microbiome affects human health has consequences for treating disease and minimizing unwanted side effects in clinical research.</p>
    </abstract>
    <abstract>
      <title>ABSTRACT</title>
      <p>Understanding how the human microbiome affects human health has consequences for treating disease and minimizing unwanted side effects in clinical research. Here, we present <italic>MetaMed</italic> (<ext-link ext-link-type="uri" xlink:href="http://metamed.rwebox.com/index">http://metamed.rwebox.com/index</ext-link>), a novel and integrative system-wide correlation mapping system to link bacterial functions and medicine therapeutics, providing novel hypotheses for deep investigation of microbe therapeutic effects on human health. Furthermore, comprehensive relationships between microbes living in the environment and drugs were discovered, providing a rich source for discovering microbiota metabolites with great potential for pharmaceutical applications.</p>
    </abstract>
    <kwd-group>
      <title>KEYWORDS</title>
      <kwd>microbiota</kwd>
      <kwd>metabolism</kwd>
      <kwd>biosynthetic gene clusters</kwd>
      <kwd>medicine therapeutics</kwd>
    </kwd-group>
    <counts>
      <count count="6" count-type="supplementary-material"/>
      <fig-count count="4"/>
      <table-count count="1"/>
      <equation-count count="0"/>
      <ref-count count="28"/>
      <page-count count="9"/>
      <word-count count="5366"/>
    </counts>
    <custom-meta-group>
      <custom-meta>
        <meta-name>cover-date</meta-name>
        <meta-value>September/October 2019</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="s1">
    <title>OPINION/HYPOTHESIS</title>
    <p>The importance of human microbiota in therapeutic outcomes is well recognized. Deciphering the effects of microbes on human health has become a challenging issue in clinical research (<xref rid="B1" ref-type="bibr">1</xref>). Microbes affect the human body through various pathways, such as by modulating host metabolism and immunity through the production of metabolites and the release of bioactive components, thereby influencing health status and disease occurrence and/or progression (<xref rid="B1" ref-type="bibr">1</xref>). Although the exact mechanism underlying such microbiota-host interactions is complex and remains largely underexplored (<xref rid="B2" ref-type="bibr">2</xref>), linking microbe metabolites to existing drugs or small molecules by taking advantage of the available annotation information on existing medicines will provide useful guidance and novel hypotheses to decipher the effect of microbes on human health (<xref rid="B3" ref-type="bibr">3</xref>).</p>
    <p>To this end, we introduced <italic>MetaMed</italic> (<italic><underline>Meta</underline>genomics <underline>Med</underline>icine</italic> mapping system), a novel and integrative system-wide correlation mapping system to link bacterial functions and medicine therapeutics. In this system, a well-defined similarity score between microbial metabolite entities and medicine entities is applied to link microbial functions and existing medicine therapeutics. We provide comprehensive and solid evidence that such a straightforward linking strategy can help to achieve accurate predictions of microbial effects on the human body. Furthermore, such predictions also help to derive hypotheses which will facilitate the discovery of microbiota metabolites with great potential for pharmaceutical applications.</p>
  </sec>
  <sec id="s2">
    <title>DEVELOPMENT OF <italic>MetaMed</italic></title>
    <p>If microbial metabolites and medicine molecules share similar structures and perturbation transcriptional profiles, they will likely have similar functions in the human body. In our study, we first collected 1,157 microbe biosynthetic gene clusters (BGCs) as well as their metabolites from MIBiG (<xref rid="B4" ref-type="bibr">4</xref>) and 8,226 drugs from DrugBank (<xref rid="B5" ref-type="bibr">5</xref>). It should be noted that MIBiG provides comprehensive annotations to indicate the laboratory conditions for metabolites produced by microbes. Other information related to the conditions of microbes producing certain metabolites in the human body is not available yet. Therefore, <italic>MetaMed</italic> is designed to present the potential ability for microbes to produce certain metabolites and encourage further investigations on them.</p>
    <p>We then defined a similarity score by considering both the molecular structure (<xref rid="B6" ref-type="bibr">6</xref>) and perturbation transcriptional expression profiles (<xref rid="B7" ref-type="bibr">7</xref>) to connect microbe functions with available drug annotation information (see <xref ref-type="supplementary-material" rid="textS1">Text S1</xref> in the supplemental material). We eventually obtained a total of 1,193,324 pairs for evaluating the potential connections between metabolites and drug entities, ranked by our well-defined similarity score. We leveraged KEGG pathway annotations to justify our proposed <italic>MetaMed</italic> score schema. We defined a metabolite and a drug sharing at least one disease-related KEGG pathway as holding a similar function, and such drug-metabolite pairs are taken as the positive samples in the benchmark, while the other metabolite-drug pairs which do not share any disease-related KEGG pathways are taken as the negative samples. We ranked all predicted drug-metabolite pairs by their <italic>MetaMed</italic> similarity scores and evaluated the prediction precision above a certain <italic>MetaMed</italic> score threshold. As a result, the precision is 100% when the <italic>MetaMed</italic> score is above 0.9 (32/32). The precision is 83% when the <italic>MetaMed</italic> score is over 0.8 (45/54) and 48% when it is over 0.7 (95/199). The precision drops to 34% when the <italic>MetaMed</italic> score is over 0.6 (41/735). These data indicate that a higher <italic>MetaMed</italic> score represents a higher possibility to achieve reliable metabolite-drug pair prediction results with similar drug-related functions as indicated by the KEGG pathway annotations (see Fig. 2a). Taken together, our <italic>MetaMed</italic> similarity score can effectively distinguish high-potential metabolite-drug linkages from negative ones, which can be applied to identify metabolites with potential therapeutic effects effectively.</p>
    <supplementary-material content-type="local-data" id="textS1">
      <object-id pub-id-type="doi">10.1128/mSystems.00413-19.1</object-id>
      <label>TEXT S1</label>
      <p>Supplemental methods. Download <inline-supplementary-material id="txS1" mimetype="application" mime-subtype="pdf" xlink:href="mSystems.00413-19-s0001.pdf" content-type="local-data">Text S1, PDF file, 0.2 MB</inline-supplementary-material>.</p>
      <permissions>
        <copyright-statement>Copyright © 2019 Zhao et al.</copyright-statement>
        <copyright-year>2019</copyright-year>
        <copyright-holder>Zhao et al.</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
        </license>
      </permissions>
    </supplementary-material>
    <p>We further correlated the microbe functions with related drug effects by integrating various existing annotation information from MIBiG, LINCS, DrugBank, SIDER, etc. (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>) (<xref ref-type="fig" rid="fig1">Fig. 1</xref>; <xref ref-type="supplementary-material" rid="textS1">Text S1</xref>), resulting in a systematic mapping system, <italic>MetaMed</italic>, including the following links: microbe-drug, microbe-treatment indications, microbe-side effects, and microbe-immune status transition.</p>
    <fig id="fig1" orientation="portrait" position="float">
      <label>FIG 1</label>
      <caption>
        <p>General pipeline for mapping microbe-medicine correlations. (a) Schematic overview of the data integration and processing steps. (b) Schematic depiction of the matching algorithm and score distribution. Through the similarity score calculated by the compound’s structure and gene expression profiles, a total of 1,193,324 microbe-drug pairs are presented in <italic>MetaMed</italic>. (c) A cartoon summary of the methods and integrated databases in <italic>MetaMed</italic>.</p>
      </caption>
      <graphic xlink:href="mSystems.00413-19-f0001"/>
    </fig>
  </sec>
  <sec id="s3">
    <title>NOVEL FINDINGS AND HYPOTHESES PROVIDED BY <italic>MetaMed</italic></title>
    <sec id="s3.1">
      <title><italic>Actinobacteria</italic> and <italic>Ascomycota</italic> are two phyla of microbes with metabolites enriched with potential therapeutic effect on human health.</title>
      <p>To examine the global landscape of the entity relationships in <italic>MetaMed</italic>, we first applied the similarity score as a filter and organized the sets of drugs and microbial metabolites with a score cutoff of 0.6 by applying our developed biclustering algorithm (QUBIC for <underline>qu</underline>alitative <underline>bic</underline>lustering algorithm) (<xref rid="B10" ref-type="bibr">10</xref>) (<xref ref-type="fig" rid="fig2">Fig. 2b</xref>). QUBIC helps to clearly decipher the underlying pattern of microbe-drug relationships simultaneously from two perspectives. We found that microbes with similar phylum classes clustered together and correlated with certain drug categories with similar therapeutic effects. It is clear that the phylum <italic>Actinobacteria</italic> is enriched to be a microbe cluster with certain therapeutic indications (<xref ref-type="fig" rid="fig2">Fig. 2b</xref>). These clustered microbes with similar functional metabolites provide the most important resources of lead compound discovery. In addition, an overview of all the predicted connections above a similarity threshold (similarity score ≥0.6, <xref ref-type="fig" rid="fig2">Fig. 2c</xref>) is presented to cluster these drugs and microbes by therapeutic class and microbe phylum. In total, there were nine microbe categories at the phylum level (<xref ref-type="fig" rid="fig2">Fig. 2c</xref>). Our analysis revealed that microbes in <italic>Actinobacteria</italic> produce molecules with functions similar to anti-infective, antineoplastic, and immunomodulating drugs. This finding is consistent with previous studies (<xref rid="B11" ref-type="bibr">11</xref>) reporting that <italic>Actinobacteria</italic> are efficient producers of new secondary metabolites that exhibit a wide range of biologic activities, including antibacterial, antifungal, anticancer, antitumor, and anti-inflammatory activities. In addition, our analysis provided new clues for discovering potential bacterial lead producers with other therapeutic functions; e.g., microbes in <italic>Ascomycota</italic> and their enriched metabolites are potential sources with functions similar to those of cardiovascular system, anti-infective, antineoplastic, and immunomodulating drugs. We further defined the microbe hubs based on interactions with the greatest number of drug types, which were hypothesized to have the largest effects in humans. On the other hand, microbe islands were defined on the basis of interacting with the lowest number of drugs (<xref ref-type="fig" rid="fig2">Fig. 2d</xref>; <xref ref-type="supplementary-material" rid="tabS1">Table S1</xref>).</p>
      <fig id="fig2" orientation="portrait" position="float">
        <label>FIG 2</label>
        <caption>
          <p>Global landscape of the entity relationships in <italic>MetaMed</italic>. (a) Precision-score curve for <italic>MetaMed</italic> predictions. The precision-score plot shows the precision above a certain <italic>MetaMed</italic> score justified by KEGG annotations. The <italic>x</italic> axis corresponds to 1 − <italic>MetaMed</italic> score. The <italic>y</italic> axis corresponds to the precision of metabolite-drug pair predictions above a certain score. (b) Biclustering results of the microbes and drugs predicted by the similarity score (cutoff = 0.6). Microbes are labeled by phylum, and single-letter codes for each drug follow the anatomic therapeutic classification system. Therapeutic classes include the following: H, systemic hormonal preparations, excluding sex hormones and insulins; V, various; B, blood and blood-forming organs; P, antiparasitic products; M, musculoskeletal system; L, antineoplastic and immunomodulating agents; G, genitourinary system and sex hormones; R, respiratory system; A, alimentary tract and metabolism; D, dermatologicals; J, anti-infectives for systemic use; S, sensory organs; N, nervous system; C, cardiovascular system. (c) Circular layout of the predicted connections between microbes and drugs (all connections with a similarity score of ≥0.6). Line widths correspond to the number of interactions. The diagram is organized by sorting the microbes clockwise (drugs counterclockwise) in order of decreasing number of connections. Single-letter codes for each drug follow the anatomic therapeutic classification system. (d) Subnetwork showing the microbe hubs and islands (rectangular nodes in the center and periphery, respectively) and their predicted interactions with drug subsets (circles). Each rectangular node represents a single microbe in the phylum (e.g., the upper center node labeled as <italic>Actinobacteria</italic> actually represents the microbe <named-content content-type="genus-species">Streptomyces lusitanus</named-content>, and the lower center node labeled as <italic>Ascomycota</italic> actually represents the microbe <named-content content-type="genus-species">Aspergillus fumigatus</named-content>).</p>
        </caption>
        <graphic xlink:href="mSystems.00413-19-f0002"/>
      </fig>
      <supplementary-material content-type="local-data" id="tabS1">
        <object-id pub-id-type="doi">10.1128/mSystems.00413-19.2</object-id>
        <label>TABLE S1</label>
        <p>List of microbe hubs and islands and their predicted interactions with drug subsets. The predicted connections above a similarity threshold (0.6) are presented to cluster the drugs and microbes by therapeutic class and microbe phylum. Microbe hubs are those microbes identified with the highest interaction number for drug types. Microbe islands are those microbes identified with the lowest interaction number for drug types. Download <inline-supplementary-material id="tS1" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" xlink:href="mSystems.00413-19-st001.xlsx" content-type="local-data">Table S1, XLSX file, 0.01 MB</inline-supplementary-material>.</p>
        <permissions>
          <copyright-statement>Copyright © 2019 Zhao et al.</copyright-statement>
          <copyright-year>2019</copyright-year>
          <copyright-holder>Zhao et al.</copyright-holder>
          <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
            <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
          </license>
        </permissions>
      </supplementary-material>
    </sec>
    <sec id="s3.2">
      <title>Certain microbes generate secondary metabolites as potential resources for new drug discovery.</title>
      <p>Based on the similarity cutoff of 0.9 for metabolite-drug pairs, <italic>MetaMed</italic> obtains 156 meaningful microbe-drug linkages (<xref rid="tab1" ref-type="table">Table 1</xref>; <xref ref-type="supplementary-material" rid="tabS2">Table S2</xref>). Among them, the similarity scores of 60 microbe-drug pairs were 1.0 (38.5%, 60/156), indicating that those drugs were originally isolated from these microbes or that these microbes can generate secondary metabolites that are exactly the same as the drugs. Of the 60 microbes, 41 (68.3%, 41/60) are already annotated to produce the corresponding drugs in DrugBank, while the remaining 17 (28.3%, 17/60) are novel identifications annotated to produce the corresponding drugs by <italic>MetaMed</italic>. For another 96 microbe-drug pairs, their similarity score was lower than 1.0 while still maintaining similarity over 0.9. Sixty-six of these microbes (68.8%, 66/96) are reported in the literature to have similar therapeutic indications as those of the corresponding drugs (<xref ref-type="fig" rid="fig3">Fig. 3a</xref>, <xref rid="tab1" ref-type="table">Table 1</xref>, and <xref ref-type="supplementary-material" rid="tabS2">Table S2</xref>). Our analysis reveals that these microbes can generate secondary metabolites that are similar to the corresponding drugs. We recommend that users focus on such pairs, since they are potential sources for new drug discovery.</p>
      <table-wrap id="tab1" orientation="portrait" position="float">
        <label>TABLE 1</label>
        <caption>
          <p>Summary of selected connections between microbes and drugs</p>
        </caption>
        <alternatives>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col span="1"/>
              <col span="1"/>
              <col span="1"/>
              <col span="1"/>
              <col span="1"/>
              <col span="1"/>
              <col span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="2" colspan="1"><italic>MetaMed</italic> prediction</th>
                <th colspan="2" rowspan="1">Score = 1.0<hr/></th>
                <th colspan="2" rowspan="1">0.9 &lt; score &lt; 1.0<hr/></th>
                <th colspan="2" rowspan="1">Total<hr/></th>
              </tr>
              <tr>
                <th rowspan="1" colspan="1">Predicted</th>
                <th rowspan="1" colspan="1">DrugBank<break/>validated</th>
                <th rowspan="1" colspan="1">Predicted</th>
                <th rowspan="1" colspan="1">Literature<break/>validated</th>
                <th rowspan="1" colspan="1">Predicted</th>
                <th rowspan="1" colspan="1">Validated</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">No. of microbe-drug<break/>linkages</td>
                <td rowspan="1" colspan="1">60</td>
                <td rowspan="1" colspan="1">41</td>
                <td rowspan="1" colspan="1">96</td>
                <td rowspan="1" colspan="1">66</td>
                <td rowspan="1" colspan="1">156</td>
                <td rowspan="1" colspan="1">107</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">No. of microbes with<break/>disease treatment effects</td>
                <td rowspan="1" colspan="1">45</td>
                <td rowspan="1" colspan="1">29</td>
                <td rowspan="1" colspan="1">72</td>
                <td rowspan="1" colspan="1">71</td>
                <td rowspan="1" colspan="1">117</td>
                <td rowspan="1" colspan="1">100</td>
              </tr>
            </tbody>
          </table>
          <graphic xlink:href="mSystems.00413-19-t0001"/>
        </alternatives>
      </table-wrap>
      <fig id="fig3" orientation="portrait" position="float">
        <label>FIG 3</label>
        <caption>
          <p>Validation of the <italic>MetaMed</italic> prediction results. (a) Most of the microbe-drug pairs can be validated by DrugBank or published literature. The first bar indicates that 60 pairs have a similarity of 1.0. The second bar indicates that 96 pairs have a similarity of &lt;1.0. (b) Validation results of the effect of <italic>B. coagulans</italic> on IBS. The <italic>x</italic> axis corresponds to treatment weeks. The <italic>y</italic> axis corresponds to the mean abdominal pain scores and mean bloating scores. (c) Validation results of the effect of <italic>B. coagulans</italic> on IBS. The <italic>x</italic> axis corresponds to treatment weeks. The <italic>y</italic> axis corresponds to the mean bloating scores.</p>
        </caption>
        <graphic xlink:href="mSystems.00413-19-f0003"/>
      </fig>
      <supplementary-material content-type="local-data" id="tabS2">
        <object-id pub-id-type="doi">10.1128/mSystems.00413-19.3</object-id>
        <label>TABLE S2</label>
        <p>Predictions of microbe-drug linkages above the similarity score (0.9) and their validations by published literature. Novel identifications of microbes generating secondary metabolites similar to the corresponding drugs are marked gray. Download <inline-supplementary-material id="tS2" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" xlink:href="mSystems.00413-19-st002.xlsx" content-type="local-data">Table S2, XLSX file, 0.02 MB</inline-supplementary-material>.</p>
        <permissions>
          <copyright-statement>Copyright © 2019 Zhao et al.</copyright-statement>
          <copyright-year>2019</copyright-year>
          <copyright-holder>Zhao et al.</copyright-holder>
          <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
            <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
          </license>
        </permissions>
      </supplementary-material>
    </sec>
    <sec id="s3.3">
      <title><italic>MetaMed</italic> identifies microbes with disease treatment effects.</title>
      <p>Based on the 156 microbe-drug pairs identified, <italic>MetaMed</italic> directly predicts 117 microbes with disease treatment effects (<xref rid="tab1" ref-type="table">Table 1</xref>; <xref ref-type="supplementary-material" rid="tabS3">Table S3</xref>) by leveraging the drug annotation information (<xref ref-type="fig" rid="fig1">Fig. 1</xref> and <xref ref-type="supplementary-material" rid="textS1">Text S1</xref>). Among them, 113 microbes exist in the environment, and they cannot survive in the gut. Their metabolites, however, can be ingested as compound treatments for the corresponding diseases. For certain microbial metabolites which are not available for ingestion, future studies are needed to determine their ingestion mechanisms. Among these 113 microbes, metabolites from 29 (25.7%, 29/113) are already annotated with their disease treatment effects in DrugBank as these metabolites are identical to the drugs. Another group of metabolites derived from 71 microbes (62.8%, 71/113) was also validated for disease treatment by literature-based evidence (<xref rid="tab1" ref-type="table">Table 1</xref>; <xref ref-type="supplementary-material" rid="tabS3">Table S3</xref>). In total, there is evidence to support that the secondary metabolites of 100 microbes (88.5%, 100/113) can be used to treat corresponding diseases. <italic>MetaMed</italic> predicts that another two endogenous microbes, i.e., <named-content content-type="genus-species">Bacillus coagulans</named-content> and <named-content content-type="genus-species">Escherichia coli</named-content>, which exist in the human gut, can treat irritable bowel syndrome (IBS) with a high score of 0.92 and 1.0, respectively. These predictions were validated by two clinical studies (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). One study treated 44 IBS patients with either <italic>B. coagulans</italic> (<italic>n </italic>=<italic> </italic>22) or placebo (<italic>n </italic>=<italic> </italic>22) (<xref rid="B12" ref-type="bibr">12</xref>). Significant alleviation (<italic>P &lt; </italic>0.01) in IBS symptoms, like abdominal pain and bloating, was achieved in IBS patients compared with control patients (<xref ref-type="fig" rid="fig3">Fig. 3b</xref> and <xref ref-type="fig" rid="fig3">c</xref>). Another clinical study revealed therapeutic effects of <named-content content-type="genus-species">E. coli</named-content> on IBS, especially in patients with altered enteric microflora (<xref rid="B13" ref-type="bibr">13</xref>).</p>
      <supplementary-material content-type="local-data" id="tabS3">
        <object-id pub-id-type="doi">10.1128/mSystems.00413-19.4</object-id>
        <label>TABLE S3</label>
        <p>Predictions of microbes with disease treatment effects above the score 0.9 and their validations by published literature. Novel identifications of microbes with similar therapeutic indications as those of the corresponding drugs are marked gray. Download <inline-supplementary-material id="tS3" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" xlink:href="mSystems.00413-19-st003.xlsx" content-type="local-data">Table S3, XLSX file, 0.03 MB</inline-supplementary-material>.</p>
        <permissions>
          <copyright-statement>Copyright © 2019 Zhao et al.</copyright-statement>
          <copyright-year>2019</copyright-year>
          <copyright-holder>Zhao et al.</copyright-holder>
          <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
            <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
          </license>
        </permissions>
      </supplementary-material>
    </sec>
    <sec id="s3.4">
      <title><italic>MetaMed</italic> identifies microbes with side effects.</title>
      <p>Based on these 156 identified microbe-drug pairs, <italic>MetaMed</italic> predicts 18 microbes with side effects (<xref ref-type="fig" rid="fig1">Fig. 1</xref>, <xref ref-type="supplementary-material" rid="textS1">Text S1</xref>, and <xref ref-type="supplementary-material" rid="tabS4">Table S4</xref>). These microbes generally exist in the environment, and their secondary metabolites may have side effects in humans. Among these 18 microbes, metabolites from 5 microbes are already annotated with their side effects in SIDER (<xref rid="B8" ref-type="bibr">8</xref>) as these metabolites are identical to the drugs. Another group of metabolites derived from two microbes that are similar to drugs was also validated with potential side effects based on published evidence. <italic>MetaMed</italic> predicts that <named-content content-type="genus-species">Streptomyces toxytricini</named-content> produces the same side effects of oily stools, diarrhea, and dyspepsia. These predictions were successfully validated in a recent study (<xref rid="B14" ref-type="bibr">14</xref>) in which the clinical drug usage of lipstatin from <italic>S. toxytricini</italic> caused unpleasant side effects like oily stools, diarrhea, and dyspepsia. <italic>MetaMed</italic> also predicts that <named-content content-type="genus-species">Streptomyces lividus</named-content> has side effects on hearing, such as hearing impairment, high-frequency deafness, tinnitus, and total deafness. Interestingly, another study (<xref rid="B15" ref-type="bibr">15</xref>) also reported that lividomycin from <italic>S. lividus</italic> has side effects on the inner ear and that care must be taken to prevent ototoxicity. The potential mechanism of the side effects of these bacteria is that the secondary metabolites of these two microbes are similar to drugs with similar side effects.</p>
      <supplementary-material content-type="local-data" id="tabS4">
        <object-id pub-id-type="doi">10.1128/mSystems.00413-19.5</object-id>
        <label>TABLE S4</label>
        <p>Predictions of microbes with side effects above the score 0.9 and their validations by published literature. Download <inline-supplementary-material id="tS4" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" xlink:href="mSystems.00413-19-st004.xlsx" content-type="local-data">Table S4, XLSX file, 0.07 MB</inline-supplementary-material>.</p>
        <permissions>
          <copyright-statement>Copyright © 2019 Zhao et al.</copyright-statement>
          <copyright-year>2019</copyright-year>
          <copyright-holder>Zhao et al.</copyright-holder>
          <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
            <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
          </license>
        </permissions>
      </supplementary-material>
    </sec>
    <sec id="s3.5">
      <title><italic>MetaMed</italic> predicts microbes with effects on immune transition.</title>
      <p><italic>MetaMed</italic> also predicts 82 microbes with effects on immune transition in human health (<xref ref-type="supplementary-material" rid="tabS5">Table S5</xref>) leveraging recently published information on the drug-immune transition (<xref rid="B9" ref-type="bibr">9</xref>) (<xref ref-type="fig" rid="fig1">Fig. 1</xref> and <xref ref-type="supplementary-material" rid="textS1">Text S1</xref>). Among them, 81 microbes exist in the environment, and they cannot survive in the human gut. The metabolites of these 81 microbes, however, can be taken as compounds with potential effects on the corresponding immune transition. Metabolites from 35 microbes (43.2%, 35/81) are already annotated with their impact on immune transitions (<xref rid="B9" ref-type="bibr">9</xref>) as these metabolites are identical to the drugs. For the only endogenous microbe identified by <italic>MetaMed</italic>, i.e., <named-content content-type="genus-species">Bacillus coagulans</named-content>, which exists in the human gut, <italic>MetaMed</italic> predicts that the microbe can increase CD4<sup>+</sup> T cells in the spleen. Interestingly, one recent clinical study (<xref rid="B16" ref-type="bibr">16</xref>) demonstrated that administering <italic>B. coagulans</italic> significantly (<italic>P</italic> &lt; 0.001) increases the population of CD4<sup>+</sup> Foxp3<sup>+</sup> T cells in the spleen.</p>
      <supplementary-material content-type="local-data" id="tabS5">
        <object-id pub-id-type="doi">10.1128/mSystems.00413-19.6</object-id>
        <label>TABLE S5</label>
        <p>Predictions of microbes with effects on immune transition based on the identified microbe-drug linkages above the similarity score 0.9 and their validations by published literature. Download <inline-supplementary-material id="tS5" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" xlink:href="mSystems.00413-19-st005.xlsx" content-type="local-data">Table S5, XLSX file, 0.06 MB</inline-supplementary-material>.</p>
        <permissions>
          <copyright-statement>Copyright © 2019 Zhao et al.</copyright-statement>
          <copyright-year>2019</copyright-year>
          <copyright-holder>Zhao et al.</copyright-holder>
          <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
            <license-p>This content is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
          </license>
        </permissions>
      </supplementary-material>
    </sec>
    <sec id="s3.6">
      <title>Linking endogenous microbe alteration information with drug therapeutics serves as a potential strategy for drug combination prediction.</title>
      <p>Alterations of endogenous microbes also affect disease treatment, and we further pointed out that linking endogenous microbe alteration information with drug therapeutics is a potential method for predicting the appropriate combination drugs for treating disease. We demonstrated this hypothesis by the following two cases. (i) Recently, two studies reported the involvement of gut microbes in regulating the efficacy of anti-CTLA-4 and anti-PDL1 cancer therapy (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). The outgrowth of <named-content content-type="genus-species">Bacteroides fragilis</named-content> was associated with the efficacy of CTLA-4 blockade in the treatment of melanoma patients with ipilimumab (<xref rid="B17" ref-type="bibr">17</xref>). Although this is a correlation study, it is reasonable to speculate that the metabolites of <named-content content-type="genus-species">B. fragilis</named-content> help to improve the treatment efficacy of CTLA-4 blockade with ipilimumab. In our study, <italic>MetaMed</italic> found that glucosamine 1-phosphate (score = 0.73, ranking first among all <named-content content-type="genus-species">B. fragilis</named-content> metabolites) and sodium stibogluconate (score = 0.70, ranking second among all <named-content content-type="genus-species">B. fragilis</named-content> metabolites) have high similarity scores with <named-content content-type="genus-species">B. fragilis</named-content> metabolites. Interestingly, some studies report that sodium stibogluconate can be used to augment the blockade of CTLA-4 by ipilimumab (<xref rid="B19" ref-type="bibr">19</xref>). The potential immunotherapy effect of glucosamine 1-phosphate awaits further validation, although its potential immunosuppressive effects and anticancer activity were reported elsewhere (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>). (ii) We also analyzed the differentially expressed microbes in human disease from metagenome-wide association study (MWAS) data (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). <italic>Enterobacteriaceae</italic> was the only bacterial family exhibiting highly increased expression in two similarly sized subgroups of women who had type 2 diabetes (T2D) with (<italic>n</italic> = 20) or without (<italic>n</italic> = 33) metformin treatment (<xref ref-type="fig" rid="fig4">Fig. 4a</xref>), and <named-content content-type="genus-species">Escherichia coli</named-content> was the most abundant genus in this case (<xref ref-type="fig" rid="fig4">Fig. 4b</xref>). In <italic>MetaMed</italic>, <named-content content-type="genus-species">E. coli</named-content> was identified to be correlated with T2D treatment effects, which is consistent with the MWAS result. <italic>MetaMed</italic> further identified that linaclotide is the drug most similar to <named-content content-type="genus-species">E. coli</named-content> metabolites (score = 1.00). We speculate that this drug could be a potential drug combination candidate for treating T2D, although no reports have been published to date. We investigated the next most similar drug, i.e., lixisenatide, which is similar to <named-content content-type="genus-species">E. coli</named-content> metabolites with a similarity score of 0.68. Surprisingly, this drug is reported to reduce blood glucose levels in patients with T2D (<xref rid="B24" ref-type="bibr">24</xref>) and is administered with metformin to improve treatment for T2D (<xref rid="B25" ref-type="bibr">25</xref>). In summary, this evidence, although limited, indicates that information linking clinical treatment-induced changes in endogenous microbes with drug annotation by <italic>MetaMed</italic> is a promising method for predicting combination drug effects.</p>
      <fig id="fig4" orientation="portrait" position="float">
        <label>FIG 4</label>
        <caption>
          <p>Validation of the <italic>MetaMed</italic> prediction of <named-content content-type="genus-species">E. coli</named-content> treating human T2D by MWAS. (a) <named-content content-type="genus-species">E. coli</named-content> at the genus level was significantly increased in the metformin group. The <italic>x</italic> axis corresponds to different microbes in the family, and “other” means that they cannot be identified at the family level. The <italic>y</italic> axis corresponds to the metagenomic read count. The <italic>P</italic> value of <italic>Enterobacteriaceae</italic> between read counts by taking the metformin group (red box plots) and read counts by taking the placebo group (blue box plots) is labeled at the top of the two box plots. (b) Most of the microbes in <italic>Enterobacteriaceae</italic> are <named-content content-type="genus-species">E. coli</named-content>. “Other” means the abundance is lower than 0.1%.</p>
        </caption>
        <graphic xlink:href="mSystems.00413-19-f0004"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="s4">
    <title>CONCLUSIONS</title>
    <p>It should be noted that <italic>MetaMed</italic> utilized metabolites produced by microbial BGCs from MIBiG as the data source, which may lead to the exclusion of certain known drugs produced by microbes without BGC information and the experimental annotations of the corresponding microbe metabolites. For all 93 drugs reported to be produced by microbes in DrugBank, <italic>MetaMed</italic> identified 41 among them. Despite the limited annotations of MIBiG for BGCs, the MIBiG database provides comprehensive experimental annotations on how microbial BGCs produce certain metabolites under certain conditions, which is the primary concern of our study here. A microbe may have the genomic ability to produce a drug, but it happens only under certain treatment or laboratory conditions. Since the MIBiG database presents comprehensive annotations of the laboratory conditions for metabolites produced by certain microbes curated from published literature, it was selected as our data source. Other databases (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>) collect many more microbes however lack such annotations. Therefore, we believe that <italic>MetaMed</italic>, which is built based on the experimental validated annotations of microbe metabolites collected from the MIBiG database, can provide a valuable and reliable resource to the whole community.</p>
    <p>To facilitate a comprehensive exploration of the systematic mapping of the microbiota functions with medicine annotations, we built the web system <italic>MetaMed</italic> V1.1 (<ext-link ext-link-type="uri" xlink:href="http://metamed.rwebox.com/index">http://metamed.rwebox.com/index</ext-link>) to allow users to browse various microbe functions and medicine annotation linkage information, as well as to calculate such linkages directly from personalized metagenomics sequencing data (Metapipe, <ext-link ext-link-type="uri" xlink:href="https://github.com/adamtongji/metapipe">https://github.com/adamtongji/metapipe</ext-link>). Novel findings and hypotheses can be obtained by analysis of such linkages, while future directions will be explored to investigate the causation between them by experimental study (<xref rid="B28" ref-type="bibr">28</xref>). In summary, <italic>MetaMed</italic> provides the first attempt to link microbiota functions with medicine therapeutics, providing novel perspectives and hypotheses for deep investigation of microbe therapeutic effects on human health. The aim of our study is to present a novel computational strategy to decipher microbe effects on human health, and we validated the identified relationships with only known literature evidences. We encourage to perform future experimental validation and investigations on these derived hypotheses or predicted results. Such knowledge will undoubtedly foster the successful application of nutritional microbiota-based therapeutics, enabling optimization of the efficacy of microbiota-interacting drugs in humans and facilitating the discovery of microbiota metabolites with great potential for pharmaceutical applications.</p>
    <sec id="s4.1">
      <title>Availability of data.</title>
      <p>The data for correlation between microbes and drug, microbial information, and drug annotation are available at <ext-link ext-link-type="uri" xlink:href="http://metamed.rwebox.com/index">http://metamed.rwebox.com/index</ext-link>. The code for calculating such linkages between microbes and drug directly from personalized metagenomics sequencing data is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/adamtongji/metapipe">https://github.com/adamtongji/metapipe</ext-link>.</p>
    </sec>
  </sec>
</body>
<back>
  <ack>
    <title>ACKNOWLEDGMENTS</title>
    <p>This work was supported by the National Major Research and Innovation Program of China (grants 2017YFC0908500 and 2016YFC1303205), the National Natural Science Foundation of China (grants 61572361 and 31671374), the Shanghai Rising-Star Program (grant 16QA1403900), the Shanghai Natural Science Foundation Program (grant 17ZR1449400), and Fundamental Research Funds for the Central Universities, China.</p>
    <p>Q.L. and S.Q. conceived the method. Q.L., H.Z., and S.F. implemented the pipeline. H.Z. and Y.Y. implemented the webserver. Z.Z., K.N., P.L., and Q.M. processed the data and also helped to implement the pipeline. Q.L., H.Z., W.J., and S.Q. wrote the manuscript with assistance from other authors.</p>
    <p>The authors declare no competing financial interests.</p>
  </ack>
  <ref-list>
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spanogiannopoulos</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bess</surname><given-names>EN</given-names></name>, <name name-style="western"><surname>Carmody</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Turnbaugh</surname><given-names>PJ</given-names></name></person-group><year>2016</year><article-title>The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism</article-title>. <source>Nat Rev Microbiol</source><volume>14</volume>:<fpage>273</fpage>–<lpage>287</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrmicro.2016.17</pub-id>.<pub-id pub-id-type="pmid">26972811</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cirstea</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Radisavljevic</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Finlay</surname><given-names>BB</given-names></name></person-group><year>2018</year><article-title>Good bug, bad bug: breaking through microbial stereotypes</article-title>. <source>Cell Host Microbe</source><volume>23</volume>:<fpage>10</fpage>–<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2017.12.008</pub-id>.<pub-id pub-id-type="pmid">29324224</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maier</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Pruteanu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kuhn</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zeller</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Telzerow</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Brochado</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Fernandez</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Dose</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Mori</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Patil</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Bork</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Typas</surname><given-names>A</given-names></name></person-group><year>2018</year><article-title>Extensive impact of non-antibiotic drugs on human gut bacteria</article-title>. <source>Nature</source><volume>555</volume>:<fpage>623</fpage>–<lpage>628</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature25979</pub-id>.<pub-id pub-id-type="pmid">29555994</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medema</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Kottmann</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Yilmaz</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cummings</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Biggins</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Blin</surname><given-names>K</given-names></name>, <name name-style="western"><surname>de Bruijn</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Chooi</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Claesen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Coates</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Cruz-Morales</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Duddela</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Düsterhus</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Fewer</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Garg</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Geiger</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gomez-Escribano</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Greule</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hadjithomas</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Haines</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Helfrich</surname><given-names>EJN</given-names></name>, <name name-style="western"><surname>Hillwig</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Ishida</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Jungmann</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kegler</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>HU</given-names></name>, <name name-style="western"><surname>Kötter</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Krug</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Masschelein</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Melnik</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Mantovani</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Monroe</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Moss</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Nützmann</surname><given-names>H-W</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pati</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Petras</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Reen</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Rosconi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Rui</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Tobias</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Tsunematsu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wiemann</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Wyckoff</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yim</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Aigle</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Apel</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Balibar</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Balskus</surname><given-names>EP</given-names></name>, <name name-style="western"><surname>Barona-Gómez</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bechthold</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bode</surname><given-names>HB</given-names></name>, <name name-style="western"><surname>Borriss</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Brady</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Brakhage</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Caffrey</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>Y-Q</given-names></name>, <name name-style="western"><surname>Clardy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cox</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>De Mot</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Donadio</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Donia</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>van der Donk</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Dorrestein</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Doyle</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Driessen</surname><given-names>AJM</given-names></name>, <name name-style="western"><surname>Ehling-Schulz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Entian</surname><given-names>K-D</given-names></name>, <name name-style="western"><surname>Fischbach</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Gerwick</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Gerwick</surname><given-names>WH</given-names></name>, <name name-style="western"><surname>Gross</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Gust</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hertweck</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Höfte</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Ju</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Katz</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kaysser</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Klassen</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Keller</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Kormanec</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kuipers</surname><given-names>OP</given-names></name>, <name name-style="western"><surname>Kuzuyama</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kyrpides</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Kwon</surname><given-names>H-J</given-names></name>, <name name-style="western"><surname>Lautru</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lavigne</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Linquan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Luzhetskyy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mahmud</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mast</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Méndez</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Metsä-Ketelä</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Micklefield</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mitchell</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Moreira</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Müller</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Neilan</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Nett</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nielsen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>O’Gara</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Oikawa</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Osbourn</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Osburne</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Ostash</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Payne</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Pernodet</surname><given-names>J-L</given-names></name>, <name name-style="western"><surname>Petricek</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Piel</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ploux</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Raaijmakers</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Salas</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Schmitt</surname><given-names>EK</given-names></name>, <name name-style="western"><surname>Scott</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Seipke</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Sherman</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Sivonen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Smanski</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Sosio</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Stegmann</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Süssmuth</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Tahlan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Truman</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Viaud</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Walton</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Walsh</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Weber</surname><given-names>T</given-names></name>, <name name-style="western"><surname>van Wezel</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Wilkinson</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Willey</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Wohlleben</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wright</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Ziemert</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zotchev</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Breitling</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Takano</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Glöckner</surname><given-names>FO</given-names></name></person-group><year>2015</year><article-title>Minimum information about a biosynthetic gene cluster</article-title>. <source>Nat Chem Biol</source><volume>11</volume>:<fpage>625</fpage>–<lpage>631</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nchembio.1890</pub-id>.<pub-id pub-id-type="pmid">26284661</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Feunang</surname><given-names>YD</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Lo</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Marcu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Grant</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Sajed</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sayeeda</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Assempour</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Iynkkaran</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Maciejewski</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gale</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cummings</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Le</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Pon</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Knox</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>M</given-names></name></person-group><year>2018</year><article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res</source><volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boström</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hogner</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schmitt</surname><given-names>S</given-names></name></person-group><year>2006</year><article-title>Do structurally similar ligands bind in a similar fashion?</article-title><source>J Med Chem</source><volume>49</volume>:<fpage>6716</fpage>–<lpage>6725</lpage>. doi:<pub-id pub-id-type="doi">10.1021/jm060167o</pub-id>.<pub-id pub-id-type="pmid">17154502</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Reid</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>NR</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Fernandez</surname><given-names>NF</given-names></name>, <name name-style="western"><surname>Rouillard</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Readhead</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Tritsch</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Hodos</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hafner</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Niepel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sorger</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Dudley</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Bavari</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Panchal</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Ma’ayan</surname><given-names>A</given-names></name></person-group><year>2016</year><article-title>L1000CDS2: LINCS L1000 characteristic direction signatures search engine</article-title>. <source>NPJ Syst Biol Appl</source><volume>2</volume>:<fpage>257</fpage>. doi:<pub-id pub-id-type="doi">10.1038/npjsba.2016.15</pub-id>.</mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuhn</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Letunic</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Bork</surname><given-names>P</given-names></name></person-group><year>2016</year><article-title>The SIDER database of drugs and side effects</article-title>. <source>Nucleic Acids Res</source><volume>44</volume>:<fpage>D1075</fpage>–<lpage>D1079</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkv1075</pub-id>.<pub-id pub-id-type="pmid">26481350</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kidd</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Wroblewska</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Boland</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Agudo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Merad</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tatonetti</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>BD</given-names></name>, <name name-style="western"><surname>Dudley</surname><given-names>JT</given-names></name></person-group><year>2016</year><article-title>Mapping the effects of drugs on the immune system</article-title>. <source>Nat Biotechnol</source><volume>34</volume>:<fpage>47</fpage>–<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nbt.3367</pub-id>.<pub-id pub-id-type="pmid">26619012</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Paterson</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name></person-group><year>2009</year><article-title>QUBIC: a qualitative biclustering algorithm for analyses of gene expression data</article-title>. <source>Nucleic Acids Res</source><volume>37</volume>:<elocation-id>e101</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkp491</pub-id>.<pub-id pub-id-type="pmid">19509312</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manivasagan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Venkatesan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sivakumar</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>S-K</given-names></name></person-group><year>2014</year><article-title>Pharmaceutically active secondary metabolites of marine actinobacteria</article-title>. <source>Microbiol Res</source><volume>169</volume>:<fpage>262</fpage>–<lpage>278</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.micres.2013.07.014</pub-id>.<pub-id pub-id-type="pmid">23958059</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hun</surname><given-names>L</given-names></name></person-group><year>2009</year><article-title>Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS</article-title>. <source>Postgrad Med</source><volume>121</volume>:<fpage>119</fpage>–<lpage>124</lpage>. doi:<pub-id pub-id-type="doi">10.3810/pgm.2009.03.1984</pub-id>.</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kruis</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Chrubasik</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Boehm</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Stange</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Schulze</surname><given-names>J</given-names></name></person-group><year>2012</year><article-title>A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome</article-title>. <source>Int J Colorectal Dis</source><volume>27</volume>:<fpage>467</fpage>–<lpage>474</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00384-011-1363-9</pub-id>.<pub-id pub-id-type="pmid">22130826</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Dubey</surname><given-names>KK</given-names></name></person-group><year>2015</year><article-title>Current trends and future prospects of lipstatin: a lipase inhibitor and pro-drug for obesity</article-title>. <source>RSC Adv</source><volume>5</volume>:<fpage>86954</fpage>–<lpage>86966</lpage>. doi:<pub-id pub-id-type="doi">10.1039/C5RA14892H</pub-id>.</mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hori</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kawamoto</surname><given-names>K</given-names></name></person-group><year>1972</year><article-title>The experimental study of the side effect of lividomycin on the inner ear</article-title>. <source>Audiol Japan</source><volume>15</volume>:<fpage>212</fpage>–<lpage>219</lpage>. doi:<pub-id pub-id-type="doi">10.4295/audiology.15.212</pub-id>.</mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><year>2017</year><article-title>Lactic acid bacteria-specific induction of CD4+Foxp3+T cells ameliorates shrimp tropomyosin-induced allergic response in mice via suppression of mTOR signaling</article-title>. <source>Sci Rep</source><volume>7</volume>:<fpage>310</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-017-02260-8</pub-id>.<pub-id pub-id-type="pmid">28331193</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vetizou</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pitt</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Daillere</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lepage</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Waldschmitt</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Flament</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Rusakiewicz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Routy</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Roberti</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Duong</surname><given-names>CPM</given-names></name>, <name name-style="western"><surname>Poirier-Colame</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Roux</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Becharef</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Formenti</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Golden</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Cording</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Eberl</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schlitzer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ginhoux</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Mani</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yamazaki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Jacquelot</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Enot</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Berard</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nigou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Opolon</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Eggermont</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Woerther</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Chachaty</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Chaput</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Robert</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mateus</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kroemer</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Raoult</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Boneca</surname><given-names>IG</given-names></name>, <name name-style="western"><surname>Carbonnel</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Chamaillard</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zitvogel</surname><given-names>L</given-names></name></person-group><year>2015</year><article-title>Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota</article-title>. <source>Science</source><volume>350</volume>:<fpage>1079</fpage>–<lpage>1084</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.aad1329</pub-id>.<pub-id pub-id-type="pmid">26541610</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Corrales</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hubert</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Aquino-Michaels</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Earley</surname><given-names>ZM</given-names></name>, <name name-style="western"><surname>Benyamin</surname><given-names>FW</given-names></name>, <name name-style="western"><surname>Lei</surname><given-names>YM</given-names></name>, <name name-style="western"><surname>Jabri</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Alegre</surname><given-names>M-L</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>EB</given-names></name>, <name name-style="western"><surname>Gajewski</surname><given-names>TF</given-names></name></person-group><year>2015</year><article-title>Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy</article-title>. <source>Science</source><volume>350</volume>:<fpage>1084</fpage>–<lpage>1089</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.aac4255</pub-id>.<pub-id pub-id-type="pmid">26541606</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borden</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Yi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lindner</surname><given-names>D</given-names></name></person-group><year>2012</year><article-title>P061 SHP-1 inhibitors to enhance signaling and IFN-Γ production by activated T cells, mediate antitumor effects of through IFN-g, and to augment blockade of CTLA-4 by ipilimumab</article-title>. <source>Cytokine</source><volume>59</volume>:<fpage>537</fpage>–<lpage>538</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cyto.2012.06.146</pub-id>.</mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Rudert</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Harnaha</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wright</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Machen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lakomy</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Robbins</surname><given-names>PD</given-names></name>, <name name-style="western"><surname>Trucco</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Giannoukakis</surname><given-names>N</given-names></name></person-group><year>2002</year><article-title>Immunosuppressive effects of glucosamine</article-title>. <source>J Biol Chem</source><volume>277</volume>:<fpage>39343</fpage>–<lpage>39349</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M204924200</pub-id>.<pub-id pub-id-type="pmid">12176986</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chesnokov</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Itakura</surname><given-names>K</given-names></name></person-group><year>2014</year><article-title>Anti-cancer activity of glucosamine through inhibition of N-linked glycosylation</article-title>. <source>Cancer Cell Int</source><volume>14</volume>:<fpage>45</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1475-2867-14-45</pub-id>.<pub-id pub-id-type="pmid">24932134</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jia</surname><given-names>H</given-names></name></person-group><year>2016</year><article-title>Metagenome-wide association studies: fine-mining the microbiome</article-title>. <source>Nat Rev Microbiol</source><volume>14</volume>:<fpage>508</fpage>–<lpage>522</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrmicro.2016.83</pub-id>.<pub-id pub-id-type="pmid">27396567</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karlsson</surname><given-names>FH</given-names></name>, <name name-style="western"><surname>Tremaroli</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Nookaew</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Bergström</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Behre</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Fagerberg</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Nielsen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bäckhed</surname><given-names>F</given-names></name></person-group><year>2013</year><article-title>Gut metagenome in European women with normal, impaired and diabetic glucose control</article-title>. <source>Nature</source><volume>498</volume>:<fpage>99</fpage>–<lpage>103</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature12198</pub-id>.<pub-id pub-id-type="pmid">23719380</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Trujillo</surname><given-names>JM</given-names></name></person-group><year>2016</year><article-title>Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness</article-title>. <source>Ther Adv Chronic Dis</source><volume>7</volume>:<fpage>4</fpage>–<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1177/2040622315609312</pub-id>.<pub-id pub-id-type="pmid">26770666</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nauck</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rizzo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bosch-Traberg</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Madsen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cariou</surname><given-names>B</given-names></name></person-group><year>2016</year><article-title>Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomized controlled clinical trial</article-title>. <source>Diabetes Care</source><volume>39</volume>:<fpage>1501</fpage>–<lpage>1509</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc15-2479</pub-id>.<pub-id pub-id-type="pmid">27311491</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magnúsdóttir</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Heinken</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kutt</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ravcheev</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Bauer</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Noronha</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Greenhalgh</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Jäger</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Baginska</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wilmes</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Fleming</surname><given-names>RMT</given-names></name>, <name name-style="western"><surname>Thiele</surname><given-names>I</given-names></name></person-group><year>2017</year><article-title>Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota</article-title>. <source>Nat Biotechnol</source><volume>35</volume>:<fpage>81</fpage>–<lpage>89</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nbt.3703</pub-id>.<pub-id pub-id-type="pmid">27893703</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blin</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Pascal Andreu</surname><given-names>V</given-names></name>, <name name-style="western"><surname>de Los Santos</surname><given-names>ELC</given-names></name>, <name name-style="western"><surname>Del Carratore</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Medema</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Weber</surname><given-names>T</given-names></name></person-group><year>2019</year><article-title>The antiSMASH database version 2: a comprehensive resource on secondary metabolite biosynthetic gene clusters</article-title>. <source>Nucleic Acids Res</source><volume>47</volume>:<fpage>D625</fpage>–<lpage>D630</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gky1060</pub-id>.<pub-id pub-id-type="pmid">30395294</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Surana</surname><given-names>NK</given-names></name>, <name name-style="western"><surname>Kasper</surname><given-names>DL</given-names></name></person-group><year>2017</year><article-title>Moving beyond microbiome-wide associations to causal microbe identification</article-title>. <source>Nature</source><volume>375</volume>:<fpage>2369</fpage>. doi:<pub-id pub-id-type="doi">10.1038/nature25019</pub-id>.</mixed-citation>
    </ref>
  </ref-list>
</back>
